Intelligence Feed event · Macro · 2026-09-24

    Vertex reports positive Phase IIb inaxaplin results for kidney disease

    Question

    Vertex reports positive Phase IIb inaxaplin results for kidney disease

    Direct answer

    Vertex Pharmaceuticals announced Phase IIb AMPLIFIED study results evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The trial showed a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) among patients presenting with modest proteinuria. In patients with concomitant AMKD and type 2 diabetes, inaxaplin demonstrated a 17.3% UACR reduction. Vertex confirmed enrollment has closed for its ongoing pivotal Phase II/III AMPLITUDE trial, advancing its commercial timeline for nephrology therapeutics.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vertex reports positive Phase IIb inaxaplin results for kidney disease”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/vertex-reports-positive-phase-iib-inaxaplin-results-for-kidney-disease-edd991

    MACRO
    Vertex reports positive Phase IIb inaxaplin results for kidney disease
    Vertex Pharmaceuticals announced Phase IIb AMPLIFIED study results evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The trial showed a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) among patients presenting with modest proteinuria. In patients with concomitant AMKD and type 2 diabetes, inaxaplin demonstrated a 17.3% UACR reduction. Vertex confirmed enrollment has closed for its ongoing pivotal Phase II/III AMPLITUDE trial, advancing its commercial timeline for nephrology therapeutics.
    VRTX
    Impact
    67
    SEP 24
    SIG
    85%
    VRTX
    Vertex reports positive Phase IIb inaxaplin results for kidney disease
    Vertex Pharmaceuticals announced Phase IIb AMPLIFIED study results evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The trial showed a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) among patients presenting with modest proteinuria. In patients with concomitant AMKD and type 2 diabetes, inaxaplin demonstrated a 17.3% UACR reduction. Vertex confirmed enrollment has closed for its ongoing pivotal Phase II/III AMPLITUDE trial, advancing its commercial timeline for nephrology therapeutics.
    → Statistically significant proteinuria reduction supports regulatory approval path for inaxaplin, de-risking Vertex's late-stage non-CF pipeline.
    Impact
    Vertex Pharmaceuticals announced Phase IIb AMPLIFIED study results evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The trial showed a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) among patients presenting with modest proteinuria. In patients with concomitant AMKD and type 2 diabetes, inaxaplin demonstrated a 17.3% UACR reduction. Vertex confirmed enrollment has closed for its ongoing pivotal Phase II/III AMPLITUDE trial, advancing its commercial timeline for nephrology therapeutics.
    Affected
    VRTX
    Transmission
    Statistically significant proteinuria reduction supports regulatory approval path for inaxaplin, de-risking Vertex's late-stage non-CF pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    VRTXpipeline net present value repricing on late-stage clinical efficacyUp1-5dAMPLIFIED study met primary endpoint with 42.7% UACR reduction; AMPLITUDE Phase II/III enrollment completed.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed522.38 2026-09-24+0.73%-2.99%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month